Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

被引:61
|
作者
Zollinger, Wendell D. [1 ]
Donets, Mikhail A. [1 ]
Schmiel, Deborah H. [1 ]
Pinto, Valerian B. [1 ]
Labrie, Joseph E., III [1 ]
Moran, Elizabeth E. [1 ]
Brandt, Brenda L. [1 ]
Ionin, Boris [1 ]
Marques, Ryan [1 ]
Wu, Max [1 ]
Chen, Ping [1 ]
Stoddard, Mark B. [1 ]
Keiser, Paul B. [1 ]
机构
[1] WRAIR, Div Bacterial & Rickettsial Dis, Silver Spring, MD 20910 USA
关键词
Neisseria meningitidis; Vaccine; Vesicles; MENINGITIDIS SEROGROUP-B; LIPOPOLYSACCHARIDE CORE OLIGOSACCHARIDES; SYNERGISTIC BACTERICIDAL ACTIVITY; NEISSERIA-MENINGITIDIS; MONOCLONAL-ANTIBODIES; PROTEIN; IMMUNOGENICITY; DISEASE; POLYSACCHARIDE; CANDIDATE;
D O I
10.1016/j.vaccine.2010.05.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A vaccine based on native outer membrane vesicles (NOMV) that has potential to provide safe, broad based protection against group B strains of Neisseria meningitidis has been developed. Three antigenically diverse group B strains of N. meningitidis were chosen and genetically modified to improve safety and expression of desirable antigens. Safety was enhanced by disabling three genes: synX, IpxL1, and IgtA. The vaccine strains were genetically configured to have three sets of antigens each with potential to induce protective antibodies against a wide range of group B strains. Preliminary immunogenicity studies with combined NOMV from the three strains confirmed the capacity of the vaccine to induce a broad based bactericidal antibody response. Analysis of the bactericidal activity indicated that antibodies to the LOS were responsible for a major portion of the bactericidal activity and that these antibodies may enhance the bactericidal activity of anti-protein antibodies. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5057 / 5067
页数:11
相关论文
共 50 条
  • [1] Immunogenicity and safety testing of an intranasal group B meningococcal native outer membrane vesicle vaccine
    Katial, RK
    Brandt, BL
    Moran, EE
    Agnello, V
    Marks, S
    Zollinger, WD
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S326 - S327
  • [2] Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine
    Katial, RK
    Brandt, BL
    Moran, EE
    Marks, S
    Agnello, V
    Zollinger, WD
    INFECTION AND IMMUNITY, 2002, 70 (02) : 702 - 707
  • [3] Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers
    Drabick, JJ
    Brandt, BL
    Moran, EE
    Saunders, NB
    Shoemaker, DR
    Zollinger, WD
    VACCINE, 1999, 18 (1-2) : 160 - 172
  • [4] Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease
    Kaaijk, Patricia
    van Straaten, Ineke
    de Waterbeemd, Bas van
    Boot, Elmieke P. J.
    Levels, Lonneke M. A. R.
    van Dijken, Harry H.
    van den Dobbelsteen, Germie P. J. M.
    VACCINE, 2013, 31 (07) : 1065 - 1071
  • [5] A MENINGOCOCCAL NATIVE OUTER MEMBRANE VESICLE VACCINE AS A PLATFORM FOR PRESENTING CONSERVED GONOCOCCAL ANTIGENS
    Moe, Gregory
    Beernink, Peter
    Vianzon, Vianca
    SEXUALLY TRANSMITTED INFECTIONS, 2019, 95 : A38 - A38
  • [6] EFFECT OF OUTER-MEMBRANE VESICLE VACCINE AGAINST GROUP-B MENINGOCOCCAL DISEASE IN NORWAY
    BJUNE, G
    HOIBY, EA
    GRONNESBY, JK
    ARNESEN, O
    HOLSTFREDRIKSEN, J
    HALSTENSEN, A
    HOLTEN, E
    LINDBAK, AK
    NOKLEBY, H
    ROSENQVIST, E
    SOLBERG, LK
    CLOSS, O
    ENG, J
    FROHOLM, LO
    LYSTAD, A
    BAKKETEIG, LS
    HAREIDE, B
    LANCET, 1991, 338 (8775): : 1093 - 1096
  • [7] Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits
    Shoemaker, DR
    Saunders, NB
    Brandt, BL
    Moran, EE
    LaClair, AD
    Zollinger, WD
    INFECTION AND IMMUNITY, 2005, 73 (08) : 5031 - 5038
  • [8] A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice
    Pajon, Rolando
    Buckwalter, Carolyn M.
    Johswich, Kay O.
    Gray-Owen, Scott D.
    Granoff, Dan M.
    VACCINE, 2015, 33 (11) : 1317 - 1323
  • [9] Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine
    Næss, LM
    Oftung, F
    Aase, A
    Wetzler, LM
    Sandin, R
    Michaelsen, TE
    INFECTION AND IMMUNITY, 1998, 66 (03) : 959 - 965
  • [10] A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease
    Su, Ee Lyn
    Snapet, Matthew D.
    EXPERT REVIEW OF VACCINES, 2011, 10 (05) : 575 - 588